Yi Hong Yao
Chief Tech/Sci/R&D Officer chez CELLULAR BIOMEDICINE GROUP, INC.
Profil
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015.
Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University.
Postes actifs de Yi Hong Yao
| Sociétés | Poste | Début |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01/08/2015 |
Anciens postes connus de Yi Hong Yao
| Sociétés | Poste | Fin |
|---|---|---|
| Medimmune, Inc. | Director/Board Member | 01/07/2015 |
Formation de Yi Hong Yao
| Boston University | Graduate Degree |
| University of Kansas | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in Rockville, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
